Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 26487

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Diagnostic
  • Biotechnology
  • bone marrow
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26487

License Grant
The Licensor hereby grants to Switzerland company an exclusive (including as to Licensor and its Affiliates) royalty-bearing license to register, distribute, market, use and sell the Products in the Territory under the Licensor'd Patent Rights and the Licensor's Technology.
License Property
Products shall mean each article of manufacture, substance, material, chemical, formulation or composition which is or includes Thalidomide as an active ingredient, including, without limitation, any composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s).

The term Products expressly excludes Thalidomide analogs.  The product is currently is under review by the European Medicines Agency (EMEA) to treat patients with newly diagnosed multiple myeloma.  Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Myeloma is part of the broad group of diseases called hematological malignancies.

IPSCIO Record ID: 70123

License Grant
The company acquired the rights to develop rHuEPO for the treatment of multiple myeloma under a research and license agreement with two other parties, one is an Israeli Licensor, the technology transfer company of the University.
License Property
rHuEPO which stands for recombinant human erythropoietin, is a hormone, produced by the kidneys, and is responsible for red blood cell production in bone marrow.

Multiple Myeloma is a severe and incurable malignant hematological cancer of plasma cells.

Field of Use
This agreement pertains to the drug industry relating to the treatment of multiple myeloma.

We were granted an Orphan-drug designation from the FDA in May 2011, for rHuEPO.

IPSCIO Record ID: 203418

License Grant
Licensor grants an exclusive, worldwide right and license under the Thalidomide Patent Rights and the Mixed Patent Rights, to make, have made, use, lease, offer for sale, sell and import Products and practice Licensed Methods in the field.
License Property
The patents relate to Thalidomide.  The term Thalidomide shall mean a compound with the chemical structure described as 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, or as otherwise defined in the Merck Index, entry 9390, 12th ed., and pharmaceutically acceptable salts thereof.

The term product shall mean any article of manufacture, substance, material, chemical, formulation or composition for use in the Field which is or includes Thalidomide as an active ingredient, including, without limitation, a composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s). The Product expressly excludes Thalidomide analogs.

Field of Use
The term Field shall mean the use of Thalidomide, alone or in combination, in humans or animals, including without limitation any and all diagnostic, prophylactic, therapeutic, and research and development uses.

THALOMID(R) (thalidomide), Licensee's lead product is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers.
Erythema nodosum leprosum is one of the most frequently used terms in the science of leprosy. It is an immune-mediated complication of leprosy presenting with inflammatory skin nodules. Immune complex production and deposition as well as complement activation have long been regarded as the principal etiology of ENL. ENL is characterised by an inflammatory infiltrate of neutrophils with vasculitis. There is deposition of immune complexes and complement together with Mycobacterium leprae antigens in the skin.

IPSCIO Record ID: 271809

License Grant
The Licensor of Denmark grants an exclusive development, manufacturing and commercialization is a global license for daratumumab.
License Property
Daratumumab, marketed as DARZALEX, is a human IgG1k monoclonal antibody, or mAb, that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of MM cells.
Field of Use
Daratumumab is for the Treatment of Multiple Myeloma.
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies.

IPSCIO Record ID: 26020

License Grant
Licensor, a non-profit health care organization, hereby grants to Licensee a world-wide, exclusive royalty-bearing license, with the right to sublicense under Licensors entire right, title and interest in and to the Analog Patents, to make, use, offer for sale, sell, import, practice, and otherwise dispose of any and all Licensed Products and Licensed Methods in the Analog Field.
License Property
Licensed Product means and includes (a) any Amino Thalidomide Product; (b) any Revimid Product; (c) any product, the making, using, offering for sale, sale, or importation of which, by an unlicensed third party, would infringe any of the Analog Patents; and (d) any product that is disclosed as a species or encompassed by a genus described at column 7, line 1 through column 11, line 50 of U.S. Patent No. 5,712,291 which will not be unreasonably interpreted to encompass products that are not genuine thalidomide analogues including, without limitation, compounds currently referred to as SelCids(TM).

Thalidomide means the chemical described as 2-(2,6- Dioxo-3-piperidinyl)-lH- isoindole-1,3(2H)-dione

Thalidomide Analog means and includes any and all analogs, metabolites, precursors, and hydrolysis products of Thalidomide, and all stereoisomers of each of the foregoing, including without limitation (a) all such compounds disclosed, generically or specifically, or claimed by any of the Analog Patents, (b) Amino Thalidomide and all stereoisomers and metabolites thereof; and (c) Revimid, and all stereoisomers and metabolites thereof.

Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of erythema nodosum leprosum (ENL; episodes of skin sores, fever, and nerve damage that occur in people with Hansen's disease [leprosy]). Thalidomide is in a class of medications called immunomodulatory agents. It treats multiple myeloma by strengthening the immune system to fight cancer cells. It treats ENL by blocking the action of certain natural substances that cause swelling.

Field of Use
Analog Field means and includes any and all uses of any Thalidomide Analog, alone or in combination, including without limitation (a) in humans and animals, and (b) for any and all diagnostic, prophylactic, therapeutic, and research and development uses.

IPSCIO Record ID: 226067

License Grant
Licensor hereby grants to Company an exclusive license (with the right to grant sublicenses) under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field.
License Property
'Technology' shall mean compounds and uses for treating p62 mediated diseases as described in the Licensed IP Rights.

LICENSED  PATENT RIGHTS
1. PCT/US2012/049911 (WO2013022919A1)
2. USSN 61/521,287
3. USSN 14/237,494
4. Chinese Patent Application No. 201280048718; Pre-grant Publ. No. 103930166

ASSIGNMENT DOCUMENTS
1. Assignment document from University of Pittsburgh to inventors (Patent family of USSN 14/237,494).
2. Assignment document from Inventors to Dr. Xiang-Qun Xie (Patent family of USSN 14/237,494) .
3. Assignment document from Dr. Xiang-Qun Xie to ID4Pharma, LLC (Patent family of USSN 14/237,494).

Licensor have developed novel chemical compounds (e.g., OXS-4235) which inhibit osteoclastic bone destruction in multiple myeloma.

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies.

The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma.

Field of Use
'Field' shall mean compounds and methods for detection, diagnosis, prognosis, monitoring or predisposition testing of any disease, state or condition in humans or other animals.

IPSCIO Record ID: 3282

License Grant
Pursuant to the License Agreement, the Licensor, an University, granted the Licensee a worldwide exclusive License, for our Licensed field, with, inter alia, the right to subLicense, or assign the License in connection with a sale or transfer, including, until April 2020.
Field of Use
The Licensee is exclusive Licensee to the intellectual property in our Licensed field of multiple myeloma and related diseases as well as to prevention and management of treatment related consequences, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).

Licensee field is diagnostics in Multiple myeloma, or MM, a hematologic, or blood, cancer that develops in the bone marrow and specifically affects the plasma cells of the bone marrow.

The Licensee Licensed field includes applications to malignant and non-malignant human or animal pathologies, including but not limited to determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen. These uses, patent, and technology rights exclude using FISH, which is Licensed to a third party.

IPSCIO Record ID: 3283

License Grant
The University hereby grants the Licensee an exclusive worldwide right and license in the Licensed field to practice under the Patent Rights and the Technology Rights and to make, have made, use, offer for sale, sell and import Licensed products or the practice of services utilizing the Licensed Processes. Licensee shall have an exclusive option to license any Invention. Licensee
shall have the right to grant sublicenses consistent with this Agreement.
License Property
United States Patent   7,668,659
Diagnosis and classification of multiple myeloma

United States Patent   7,308,364
Diagnosis of multiple myeloma on gene expression profiling

Field of Use
Licensed Field shall mean those applications of Patent Rights and/or the Technology Rights with respect to non-malignant and malignant human or animal pathologies, including but not limited to, determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient, susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen.

IPSCIO Record ID: 383557

License Grant
Licensor grants the Licensee of Japan an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Patents and Licensor Technology to develop, register and to obtain Product Registrations, use, make, have made, import, export, offer to sell, sell and have sold Products for use in the Field in the Territory.
License Property
Licensor is the owner of certain technology, including, but not limited to patents and know-how, relating to mesenchymal stem cells.

MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.

Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.

The patents include
—  Monoclonal antibodies specific for marrow-derived mesenchymal cells;
—  Uses for non-autologus mesenchymal stem cells;
—  Osteoporosis bond regeneration;
—  Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
—  Mesenchymal stem cells as immunosuppressants;
—  Regulation of Hema topoietic stem cell  differentiation by the use of human mesenchymal stem cells;
—  Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.

Field of Use
The Field means the use of MSC in or in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow.

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.

IPSCIO Record ID: 3921

License Grant
The Israel Pharma Licensee announced that it has entered into an asset purchase Agreement with the Israel Pharma Licensor for the rights to a use patent on Recombinant Erythropoietin for the prolongation of multiple myeloma MM patients' survival and improvement of their quality of life.

MM is a severe plasma cell malignancy characterized by the accumulation and proliferation of clonal plasma cells in the marrow, leading to the gradual replacement of normal hematopoiesis.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 332232

License Grant
Licensed Patents. Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under the Licensed Patents, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

Know-How License Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under Licensor’s rights in and to the Captisol Data Package and Product Know-How, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

License Property
Captisol means Captisol®, also known scientifically as sulfobutylether ß(beta) cyclodextrin, sodium salt, including all of its optical isomers, and salt, ester, and polymorphic forms.

US Serial Number 12/790,724

Compound means that certain pharmaceutical compound known as melphalan, including all of its optical isomers, and salt, ester, and polymorphic forms.

US Patent #5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US Patent #7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US Patent #7,635,773 – Sulfoalkyl ether cyclodextrin compositions

Field of Use
The Captisol-enabled melphalan product candidate is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.

IPSCIO Record ID: 25826

License Grant
The Licensor acquired development and commercialization rights to the Licensor's formulation of thalidomide in all countries outside of North America, Japan, China, Taiwan, and Korea.
License Property
Thalidomide is currently sold by the Licensor in the U.S., primarily or the treatment of multiple myeloma and certain other forms of cancer.
Field of Use
The Licensor acquires or in-licenses rights to late-stage development and approved pharmaceutical products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.